Compare Natco Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DIVIS LABORATORIES NATCO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 15.8 34.7 45.7% View Chart
P/BV x 3.1 6.7 46.8% View Chart
Dividend Yield % 1.4 0.9 155.9%  

Financials

 NATCO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
DIVIS LABORATORIES
Mar-19
NATCO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,0801,639 65.9%   
Low Rs6711,115 60.2%   
Sales per share (Unadj.) Rs592.1186.3 317.8%  
Earnings per share (Unadj.) Rs188.451.0 369.7%  
Cash flow per share (Unadj.) Rs206.357.3 360.0%  
Dividends per share (Unadj.) Rs8.2516.00 51.6%  
Dividend yield (eoy) %0.91.2 81.1%  
Book value per share (Unadj.) Rs833.6261.8 318.4%  
Shares outstanding (eoy) m36.90265.47 13.9%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.57.4 20.0%   
Avg P/E ratio x4.627.0 17.2%  
P/CF ratio (eoy) x4.224.0 17.7%  
Price / Book Value ratio x1.15.3 20.0%  
Dividend payout %4.431.4 13.9%   
Avg Mkt Cap Rs m32,311365,592 8.8%   
No. of employees `0004.811.8 40.8%   
Total wages/salary Rs m3,2565,423 60.0%   
Avg. sales/employee Rs Th4,522.54,175.1 108.3%   
Avg. wages/employee Rs Th674.0457.7 147.2%   
Avg. net profit/employee Rs Th1,439.01,141.8 126.0%   
INCOME DATA
Net Sales Rs m21,84849,463 44.2%  
Other income Rs m4041,556 26.0%   
Total revenues Rs m22,25251,019 43.6%   
Gross profit Rs m9,28418,718 49.6%  
Depreciation Rs m6621,689 39.2%   
Interest Rs m15435 440.0%   
Profit before tax Rs m8,87218,551 47.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9205,023 38.2%   
Profit after tax Rs m6,95213,527 51.4%  
Gross profit margin %42.537.8 112.3%  
Effective tax rate %21.627.1 79.9%   
Net profit margin %31.827.3 116.3%  
BALANCE SHEET DATA
Current assets Rs m21,30746,501 45.8%   
Current liabilities Rs m5,9208,468 69.9%   
Net working cap to sales %70.476.9 91.6%  
Current ratio x3.65.5 65.5%  
Inventory Days Days73131 56.0%  
Debtors Days Days10786 124.1%  
Net fixed assets Rs m14,98625,797 58.1%   
Share capital Rs m369531 69.5%   
"Free" reserves Rs m30,35368,962 44.0%   
Net worth Rs m30,76069,493 44.3%   
Long term debt Rs m00-   
Total assets Rs m37,15180,383 46.2%  
Interest coverage x58.6531.0 11.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.6 95.6%   
Return on assets %19.116.9 113.4%  
Return on equity %22.619.5 116.1%  
Return on capital %29.326.7 109.7%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m10,32241,238 25.0%   
Fx outflow Rs m2,97812,405 24.0%   
Net fx Rs m7,34328,833 25.5%   
CASH FLOW
From Operations Rs m4,6369,543 48.6%  
From Investments Rs m-11,155-6,854 162.8%  
From Financial Activity Rs m6,509-2,459 -264.7%  
Net Cashflow Rs m-18230 -7.8%  

Share Holding

Indian Promoters % 52.0 52.0 100.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.8 66.4%  
FIIs % 16.6 19.0 87.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.2 151.2%  
Shareholders   25,395 31,796 79.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

DR. LAL PATHLABS LTD at All Time High; BSE HEALTHCARE Index Up 1.7% (Market Updates)

Oct 22, 2019 | Updated on Oct 22, 2019

DR. LAL PATHLABS LTD share price has hit an all time high at Rs 1,550 (up 4.5%). The BSE HEALTHCARE Index is up by 1.7%. Among the top gainers in the BSE HEALTHCARE Index today are DR. LAL PATHLABS LTD (up 4.5%) and PFIZER (up 1.5%). The top losers include SANOFI INDIA and ABBOTT INDIA .

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Oct 22, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - NOVARTIS COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS